La sindrome nefrosica in età pediatrica

1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362(9384):629-39. 2. [No authors listed] Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978;13(2):159-65. 3. Niaudet P. Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 2009;4 (10):1547-8. 4. Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr 2004;41(10):993-1000. 5. Tsuzuki K, Tanabe M, Satoh C, et al. Betamethasone “pulse” therapy for children with idiopathic nephrotic syndrome-especially for fresh cases (author transl). Nihon Jinzo Gakkai Shi 1981;23(11):1405-13. 6. McLean TLK RH, Rasoulpour M. Intravenous methylprednisolone treatment of steroid responsive nephrotic syndrome. Pediat Res 1980;14(8):1006. 7. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatr Nephrol. 1997; 11(4):418-22. 8. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 1993;152(4):357-61. 9. Syndrome Néphrotique Idiopathique de l’Enfant. Protocole national de disgnostic et de soins pour une maladie rare. France: Haute Autorité de Santé; 2008. 10. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. Kidney Int Suppl 2012;(2):139-274. 11. Feber J, Al-Matrafi J, Farhadi E, Vaillancourt R, Wolfish N. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol 2009;24(5):1027-31. 12. Saadeh SA, Baracco R, Jain A, Kapur G, Mattoo TK, Valentini RP. Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol 2011;26(12):2167-71. 13. Mehls O, Hoyer PF. Dosing of glucocorticosteroids in nephrotic syndrome. Pediatr Nephrol 2011;26(12):2095-8. 14. Ekka BK, Bagga A, Srivastava RN. Singleversus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol 1997;11(5):597-9. 15. Li X, Li Z, Cheng Z. Treatment of children with simple nephrotic syndrom using prednison once per day.Acta Academiae Medicinae Hubei 1994;15(4):386-8. 16. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2015;3:Cd001533. 17. [No authors listed] Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. J Pediatr 1979;95(2):239-43. 18. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2000;4. 19. Teeninga N, Kist-van Holthe JE, van Rijswijk N, et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 2013; 24(1):149-59. 20. Sinha A, Saha A, Kumar M, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 2015;87(1):217-24. 21. Yoshikawa N, Nakanishi K, Sako M, et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 2015;87(1):225-32. 22. Hoyer PF. New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy. Kidney Int 2015;87(1):17-9. 23. Pasini A, Aceto G, Ammenti A, et al. Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality. Pediatr Nephrol 2015;30(1):91-101. 24. Bagga A, Ali U, Banerjee S, et al. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 2008; 45(3):203-14. 25. Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009;124(2):747-57. 26. Sinha A, Bagga A. Nephrotic syndrome. Indian J Pediatr 2012;79(8):1045-55. 27. Humphreys MH. Mechanisms and management of nephrotic edema. Kidney Int 1994; 45(1):266-81. 28. Bockenhauer D. Draining the edema: a new role for aquaretics? Pediatr Nephrol 2014;29(5):767-9. 29. McCaffrey J, Lennon R, Webb NJA. The non-immunosuppressive management of childhood nephrotic syndrome. Pediatr Nephrol 2016;31:1383-402. 30. Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone - a prospective study. Clin J Am Soc Nephrol 2009;4(5):907-13. 31. Joles JA, Rabelink TJ, Braam B, Koomans HA. Plasma volume regulation: defences against edema formation (with special emphasis on hypoproteinemia). Am J Nephrol 1993;13(5):399-412. 32. [No authors listed] Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years’ observation. Report of the International Study of Kidney Disease in Children. Pediatrics 1984;73(4):497-501. 33. Uncu N, Bülbül M, Yildiz N, et al. Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. Eur J Pediatr 2010;169(1):73-6. 34. Gulati S, Kher V, Arora P, Gupta S, Kale S. Urinary tract infection in nephrotic syndrome. Pediatr Infect Dis J 1996;15(3):237-40. 35. Alwadhi RK, Mathew JL, Rath B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health 2004; 40(1-2):28-32. 36. Nyerges G, Meszner Z, Gyarmati E, Kerpel- Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis 1988;157(2):309-13. 37. Wu HM, Tang JL, Cao L, Sha ZH, Li Y. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev 2012;4:Cd003964. 38. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 2012;9:Cd003427. 39. McIntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health 1998;34(4):314-7. 40. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000;106(2 Pt 1):367-76. 41. Goldstein SL, Somers MJ, Lande MB, Brewer ED, Jabs KL. Acyclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol 2000;14(4): 305-8. 42. Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr 2003;142(2):145-8. 43. Alpay H, Yildiz N, Onar A, Temizer H, Ozcay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2002;17(3):181-3. 44. Shroff A, Frank R, Vergara M, Gauthier B, Trachtman H. Prevention of serious bacterial infections in new-onset nephrotic syndrome: a survey of current practices. Clin Pediatr (Phila) 2002;41(1):47-9. 45. Ulinski T, Leroy S, Dubrel M, Danon S, Bensman A. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol 2008;23(7):1107-13. 46. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004;22(17-18):2209-20. 47. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999;17(Suppl 1):S85-90. 48. Tinaztepe K, Buyan N, Tinaztepe B, Akkök N. The association of nephrotic syndrome and renal vein thrombosis: a clinicopathological analysis of eight pediatric patients. Turk J Pediatr 1989;31(1):1-18. 49. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol 2000;15(1-2):74-8. 50. Andrew M, Brooker LA. Hemostatic complications in renal disorders of the young. Pediatr Nephrol 1996;10(1):88-99. 51. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012;7(3):513-20. 52. Suri D, Ahluwalia J, Saxena AK, et al. Thromboembolic complications in childhood nephrotic syndrome: a clinical profile. Clin Exp Nephrol 2014;18(5):803-13. 53. Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005;129(2):165-77. 54. Mittal A, Aggarwal KC, Saluja S, Aggarwal A, Sureka B. Platelet functions and coagulation changes in Indian children with nephrotic syndrome. J Clin Diagn Res 2013; 7(8):1647-50. 55. Remuzzi G, Marchesi D, Mecca G, de Gaetano G, Silver M. Platelet hypersensitivity in the nephrotic syndrome. Proc Eur Dial Transplant Assoc 1979;16:487-94. 56. Walter E, Deppermann D, Andrassy K, Koderisch J. Platelet hyperaggregability as a consequence of the nephrotic syndrome. Thromb Res 1981;23(6):473-9. 57. Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009;155 (1):105-10. 58. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):645S-87S. 59. Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141 (2 Suppl):e737S-801S. 60. Chan AK, Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology. Am Soc Hematol Educ Program 2012;2012:439-43. 61. Law C, Raffini L. A guide to the use of anticoagulant drugs in children. Paediatr Drugs 2015;17(2):105-14. 62. Guslandi M. Steroid ulcers: any news? World J Gastrointest Pharmacol Ther 2013;4 (3):39-40. 63. Dorlo TP, Jager NG, Beijnen JH, Schellens JH. Concomitant use of proton pump inhibitors and systemic corticosteroids. Ned Tijdschr Geneeskd 2013;157(19):A5540. 64. Munson JC, Wahl PM, Daniel G, Kimmel SE, Hennessy S. Factors associated with the initiation of proton pump inhibitors in corticosteroid users. Pharmacoepidemiol Drug Saf 2012;21(4):366-74. 65. Weinstein RS. Clinical practice. Glucocorticoid- induced bone disease. N Engl J Med 2011;365(1):62-70. 66. Gulati S, Sharma RK, Gulati K, Singh U, Srivastava A. Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. Nephrol Dial Transplant 2005;20(8):1598-603. 67. Gruppen MP, Davin JC, Oosterveld MJ, et al. Prevention of steroid-induced low bone mineral density in children with renal diseases: a systematic review. Nephrol Dial Transplant 2013;28(8):2099-106. 68. Querfeld U. Should hyperlipidemia in children with the nephrotic syndrome be treated? Pediatr Nephrol 1999;13(1):77-84. 69. Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev 2013;12. 70. Cochat P, Fargue S, Mestrallet G, et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009;24(11): 2097-108. 71. Gulati A, Bagga A, Gulati S, Mehta KP, Vijayakumar M. Management of steroid resistant nephrotic syndrome. Indian Pediatr 2009;46(1):35-47. 72. [No authors listed] The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981;98(4):561-4. 73. [No authors listed] KDIGO Clinical Practice Guideline Chapter 4: Steroid-resistant nephrotic syndrome in children. Kidney Int Suppl 2012;2(2):172-6. 74. [No authors listed] Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 1974;2(7878):423-7. 75. Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the Podo- Net registry cohort. Clin J Am Soc Nephrol 2015;10(4):592–600. 76. Bierzynska A, Soderquest K, Koziell A. Genes and podocytes - new insights into mechanisms of podocytopathy. Front Endocrinol (Lausanne) 2014;5:226. 77. [No authors listed] KDIGO Clinical Practice Guideline. Chapter 3: Steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl 2012;2(2):163-71. 78. Nammalwar BR, Vijayakumar M, Prahlad N. Experience of renal biopsy in children with nephrotic syndrome. Pediatr Nephrol 2006;21(2):286-8. 79. Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 1988; 8(2):85-9. 80. [No authors listed] KDIGO Clinical Practice Guideline. Chapter 2: General principles in the management of glomerular disease. Kidney Int Suppl 2012;2(2):156-62. 81. [No authors listed] Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981;20(6):765-71. 82. McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire. UK Pediatr Nephrol 2001;16(12):1040-4. 83. Gulati S, Sharma AP, Sharma RK, Gupta A, Gupta RK. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatr Nephrol 2002;17 (6):404-8. 84. Gulati S, Sural S, Sharma RK, Gupta A, Gupta RK. Spectrum of adolescent-onset nephrotic syndrome in Indian children. Pediatr Nephrol 2001;16(12):1045-8. 85. Baqi N, Singh A, Balachandra S, et al. The paucity of minimal change disease in adolescents with primary nephrotic syndrome. Pediatr Nephrol 1998;12(2):105-7. 86. Sorof JM, Hawkins EP, Brewer ED, Boydstun II, Kale AS, Powell DR. Age and ethnicity affect the risk and outcome of focal segmental glomerulosclerosis. Pediatr Nephrol 1998;12(9):764-8. 87. Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, Verani R. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 1999;55(5):1885-90. 88. Gipson DS, Chin H, Presler TP, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 2006;21 (3):344-9.